Clinical Trials Explained

Clinical trials are the mechanism by which medical knowledge advances — how new treatments, devices, and approaches are tested for safety and effectiveness before they can be widely used. For patients, understanding how trials work, what protections apply to participants, how to find studies relevant to their condition, and what questions to ask before enrolling is valuable whether you are actively considering participation or simply want to understand how research becomes medicine.

What clinical trials are and why they exist

A clinical trial is a structured research study conducted in human volunteers to evaluate whether an intervention — a drug, a medical device, a surgical procedure, a behavioral program, or a diagnostic tool — is safe, effective, or superior to existing alternatives. Without clinical trials, there would be no reliable way to know whether a new treatment works or is safe — anecdotal reports and laboratory results alone cannot establish this.

Trials are conducted under federal regulations, overseen by the Food and Drug Administration (FDA) and, for federally funded research, by the Department of Health and Human Services Office for Human Research Protections (OHRP). They must follow a detailed protocol that specifies the research question, who can participate, what interventions will be tested, what will be measured, and how data will be analyzed.

Trial phases

Clinical trials for drugs and biologics typically proceed through sequential phases:

Phase 1: The first human testing of a new treatment, usually in a small number of volunteers (often healthy volunteers, sometimes patients when the condition warrants it). The primary focus is safety — determining how the body handles the treatment, what doses are tolerable, and what side effects occur.

Phase 2: Testing in a larger group of patients with the condition of interest. The focus expands to include early signs of effectiveness and continues to evaluate safety. Phase 2 trials help determine appropriate dosing ranges and identify which patient populations may benefit.

Phase 3: Larger, randomized controlled trials comparing the new treatment against a standard treatment (or placebo where no standard exists). These trials — sometimes involving hundreds to thousands of participants across multiple sites — provide the primary evidence of effectiveness and safety needed for regulatory approval.

Phase 4: Post-marketing studies conducted after a treatment has received regulatory approval. They continue to monitor safety and effectiveness in larger, more diverse populations and in real-world conditions.

Ethical protections for participants

Federal regulations governing human research — codified in 45 CFR 46 (the Common Rule) and 21 CFR 50 and 56 for FDA-regulated research — establish a framework of protections for research participants:

Institutional Review Board (IRB) oversight: Every clinical trial must be reviewed and approved by an independent ethics committee (IRB) before it can begin, and the IRB monitors the trial during its conduct. IRBs evaluate whether the risks are justified by the potential benefits and whether participants will be appropriately protected and informed.

Informed consent: Before enrolling in a trial, you must receive a thorough explanation of the study — its purpose, procedures, duration, risks, potential benefits, alternatives, and your rights as a participant. You must have the opportunity to ask questions and must sign a consent form documenting your agreement. Informed consent is not a one-time event — you can ask questions and withdraw at any time during the trial.

Right to withdraw: You can withdraw from a clinical trial at any time for any reason, without penalty and without affecting your access to standard care. Withdrawing from a research study does not affect your relationship with your regular healthcare providers.

Confidentiality: Your research data must be protected. In most trials, your medical information is identified by a code rather than your name in the research data. Researchers are prohibited from disclosing your participation without your consent.

Insurance coverage for trial participation

The ACA requires most health plans to cover the routine costs of care associated with qualifying clinical trials. Routine costs are the services — lab tests, doctor visits, hospitalizations — that you would receive as part of your standard medical care for your condition, regardless of whether you were in a trial. Plans cannot:

• Deny or limit coverage solely because you are participating in a qualifying trial
• Terminate coverage because you are participating
• Discriminate against you based on trial enrollment

However, insurance does not cover the experimental drug or device itself (typically funded by the trial sponsor), travel costs, or services that are only needed because of the research protocol (such as extra study visits beyond standard care).

Before enrolling, ask both the trial coordinator and your insurer which costs will be covered by each party.

Finding a clinical trial

ClinicalTrials.gov, maintained by the National Library of Medicine (part of NIH), is the central registry for clinical trials conducted in the US and worldwide. The registry contains information about trials’ purposes, eligibility criteria, locations, phases, and status (recruiting, not yet recruiting, completed). You can search by:

• Medical condition or disease
• Treatment or intervention
• Geographic location or distance
• Age group and other eligibility factors

Your own physician is another important resource — they may be aware of trials relevant to your specific diagnosis and can help evaluate whether a trial is appropriate for you based on your full medical history.

Comparing trial phases: what each means for participants

Each phase of a clinical trial differs in purpose, size, participant profile, and what rights and protections apply. Understanding these differences helps you evaluate what you are being invited into.

Feature	Phase 1	Phase 2	Phase 3	Phase 4
Primary question	Is it safe? What dose is tolerable?	Does it show early signs of working? At what dose?	Is it effective compared to standard treatment?	How does it perform in the real world post-approval?
Typical participant count	20–80	100–300	Hundreds to thousands	Thousands or more
Participant profile	Often healthy volunteers; sometimes patients	Patients with the target condition	Patients with the target condition	Patients prescribed the drug post-approval
Regulatory significance	First human data	Dose-ranging; early efficacy signal	Pivotal evidence for FDA approval	Post-market safety surveillance
Randomization	Usually not	Sometimes	Often (randomized controlled trial)	Often observational or registry-based
Investigational treatment covered by sponsor	Yes	Yes	Yes	Sometimes
IRB oversight required	Yes	Yes	Yes	Yes, if research-classified

In general, Phase 1 carries the most uncertainty about side effects; Phase 3 provides the strongest evidence of benefit because it compares the new treatment directly to existing standard care. Phase 4 studies are often the largest in scale but may carry less individual uncertainty because the drug is already approved.

What this looks like in practice

Imagine Sarah, a 49-year-old with relapsed ovarian cancer who has completed two prior lines of chemotherapy without lasting response. Her oncologist mentions that a Phase 3 randomized controlled trial is recruiting at a nearby academic cancer center, comparing a new targeted therapy to the current standard second-line chemotherapy. Sarah reviews the ClinicalTrials.gov listing (which she finds by entering the NCT number her oncologist provides) and sees that the trial has two arms — the experimental drug and standard chemotherapy — and that assignment is randomized, meaning there is a chance she will receive the standard treatment rather than the new drug.

Sarah schedules a meeting with the trial’s principal investigator. The PI walks her through the consent form over 45 minutes, answering questions about the randomization process, the schedule of study visits (every three weeks for the first six months), the procedures covered by the sponsor, and what happens if she needs to withdraw. The PI also explains that her insurer is required under ACA to cover the routine costs of care — her regular oncology visits, labs, and scans — even though she is in a trial. The experimental drug itself is provided free of charge by the trial sponsor.

Sarah decides to enroll. She signs the consent form understanding she may receive either treatment, knowing she can withdraw at any time, and with the study coordinator’s contact number saved in her phone for any questions. The process — from ClinicalTrials.gov search to signature — took about three weeks.

Step by step: evaluating and enrolling in a clinical trial

1. Identify potentially relevant trials. Search ClinicalTrials.gov using your condition, your location, and any treatment type you are interested in. Filter by “Recruiting” status and your age group. Your oncologist, specialist, or primary care provider may also refer you directly.
2. Review the trial record. Read the purpose, eligibility criteria (inclusion and exclusion criteria), study design, phase, and the “Contacts and Locations” section to find the nearest site. Note the NCT number for your records.
3. Contact the study coordinator. Call or email the contact listed in the trial record to ask whether you may be eligible and to schedule a pre-screening conversation. The coordinator can clarify eligibility before you invest significant time.
4. Consult your own physician. Before the trial screening visit, discuss the trial with your regular provider to get their perspective on whether it is appropriate given your full medical history and current treatment.
5. Attend the screening visit and review the consent form. The trial team will assess your eligibility through medical review, labs, or other tests. If eligible, you will review the informed consent document in detail. Take your time — ask every question you have, and consider bringing a support person.
6. Sign informed consent only when you are comfortable. Signing the consent form is the formal act of enrollment. You are not obligated to enroll even if you are eligible. The consent is not a waiver of your legal rights; it is documentation that you were informed and agreed to participate.
7. Keep a record of your participation. Maintain a copy of the signed consent form, the NCT number, the principal investigator’s contact information, and any study schedules. Know how to reach the study team at any time, including after hours for medical concerns.

Documents and terms you’ll see

When exploring or participating in a clinical trial, you will encounter documents and terms including:

• Clinical Trial — A structured research study in human volunteers evaluating the safety, effectiveness, or comparative value of a medical intervention
• Informed Consent — The process and document by which a participant confirms they have received, understood, and agreed to the trial’s purpose, procedures, risks, and their rights before enrollment
• Institutional Review Board — The independent ethics committee that reviews and approves clinical research to ensure participant protections are in place before a trial begins
• Protocol — The detailed written plan for a clinical trial specifying the research question, design, eligibility criteria, interventions, outcomes, and data collection procedures
• Principal Investigator — The lead researcher responsible for the conduct of the trial at a given site; the person whose name appears at the top of the study team listing
• NCT Number — The unique eight-digit identifier (e.g., NCT12345678) assigned to each trial registered at ClinicalTrials.gov; use it to find the exact study record